ARANESP® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.
EPOGEN® (epoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis to decrease the need for READ MORE
EPOGEN® (epoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis to decrease the need for red blood cell (RBC) transfusion.
Limitations of Use:
Reinforce your understanding of anemia in
CKD and build your treatment knowledge
with virtual education programs from your
Amgen inside sales team.
In the last 20 years, even in the wake of natural disasters and other disruptive events,
customers have not experienced a supply shortage of ARANESP® or EPOGEN®.2,†
Learn more about Amgen manufacturing at amgenbiotech.comLEARN MORE
*Based on 99.9% of product shipped to Amgen Authorized Distributors of Record only.
†US wholesalers only (data through March 5, 2021).
Designed specifically for nephrology healthcare providers, AnemiaHUB.com is your comprehensive source for anemia management education.
Not an Anemia HubTM member? Register here
ARANESP® (darbepoetin alfa) and EPOGEN® (epoetin alfa) Important Safety Information, including Boxed WARNINGS
WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
Chronic Kidney Disease: